Published in J Neurooncol on October 28, 2014
Temporally-Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res (2017) 0.95
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget (2016) 0.90
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget (2015) 0.86
Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res (2016) 0.81
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol (2017) 0.79
Chordoma: The Quest for Better Treatment Options. Oncol Ther (2016) 0.75
First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncoimmunology (2017) 0.75
A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. J R Soc Interface (2017) 0.75
Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer. Cell Rep (2017) 0.75
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76
Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control (2001) 4.74
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res (2011) 2.05
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology (2013) 1.35
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
The pathology of the human notochord. J Pathol (1993) 1.16
Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg (2011) 1.10
Molecular characterization of putative chordoma cell lines. Sarcoma (2010) 1.09
A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet (2012) 1.07
Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol (2012) 1.05
Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology (2013) 1.04
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol (2010) 1.04
B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol (2009) 1.01
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget (2013) 0.99
Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp (2013) 0.97
Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. Hum Pathol (2013) 0.94
Erlotinib inhibits growth of a patient-derived chordoma xenograft. PLoS One (2013) 0.90
The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol (2013) 0.87
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology. PLoS One (2013) 0.83
Evaluation of a new concept for the management of skull base chordomas and chondrosarcomas. J Neurosurg (2005) 0.83
The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One (2013) 0.80
Decision-making process for the treatment of intracranial chordomas. World Neurosurg (2013) 0.77
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Universal definition of myocardial infarction. Circulation (2007) 11.69
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron (2006) 5.34
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol (2006) 4.72
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Pediatric intracranial aneurysms: durability of treatment following microsurgical and endovascular management. J Neurosurg (2006) 3.73
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer (2002) 3.23
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Autoimmune hypophysitis. Endocr Rev (2005) 2.86
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol (2005) 2.58
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2011) 2.39
Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol (2003) 2.37
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Angiocentric glioma: a case series. J Neurosurg Pediatr (2009) 2.21
Seizure control for patients undergoing meningioma surgery. World Neurosurg (2012) 2.19
Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer (2004) 2.11
The transconjunctival transorbital approach: a keyhole approach to the midline anterior skull base. World Neurosurg (2012) 2.09
Integrative model of genomic factors for determining binding site selection by estrogen receptor-α. Mol Syst Biol (2010) 2.04
"Any possible restoration of function could not occur": Harvey Cushing and the early description of brain death. World Neurosurg (2011) 2.03
Intraoperative changes in transcranial motor evoked potentials and somatosensory evoked potentials predicting outcome in children with intramedullary spinal cord tumors. J Neurosurg Pediatr (2014) 2.03
Diagnosis and management of sacral Tarlov cysts. Case report and review of the literature. Neurosurg Focus (2003) 2.01
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol (2004) 1.85
Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery (2009) 1.79
High-grade astrocytoma in very young children. Pediatr Blood Cancer (2007) 1.77
PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood (2009) 1.74
Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery (2008) 1.72
Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg (2012) 1.72
Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study. Pediatr Dev Pathol (2007) 1.70
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol (2008) 1.67
The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol (2003) 1.66
c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res (2006) 1.66
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65
Combined microsurgical and endovascular management of complex intracranial aneurysms. Neurosurgery (2003) 1.64
Primary Intraosseous Skull Base Cavernous Hemangioma: Case Report. Skull Base (2003) 1.63
Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. Clin Cancer Res (2007) 1.62
Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol (2004) 1.62
Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J (2010) 1.61
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56
Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer (2008) 1.56
Introducer catheter for fiberoptic intubation does exist. Anesth Analg (2006) 1.56
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
The extended retrosigmoid approach for neoplastic lesions in the posterior fossa: technique modification. Neurosurg Rev (2010) 1.54
Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet (2002) 1.54
Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol (2012) 1.53
Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis (2010) 1.53
Predictors of length of stay in patients having elective colorectal surgery within an enhanced recovery protocol. Int J Surg (2010) 1.52